Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | SVP, Alks Inc; CFO ALKS | May 14, 2020 | May 14, 2020 |
| Amylyx Pharmaceuticals, Inc.AMLX · Entity 259 | Chief Financial Officer | September 10, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date May 14, 2020 · Filed May 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 91,828 |
Reported balance
After 2020-05-14 transaction · row 1
1 source rowRow 1 · 2020-05-14 · Exercise / conversion · Acquired 21,983 · Balance 91,828 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.74 · Expires 2020-05-17 | Direct | 0 |
Reported balance
After 2020-05-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-05-14 · Exercise / conversion · Disposed 21,983 · Balance 0 F3: These options are fully vested in accordance with their terms. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy 2018 GRAT No. 2 | 1,669 |
Reported balance
Holding disclosure · report date 2020-05-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,669 F1: Shares held by James M. Frates 2018 Grantor Retained Annuity Trust No. 2 dated May 25, 2018 (the "2018 GRAT No. 2"). The Reporting Person is a trustee and beneficiary of the 2018 GRAT No. 2 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2018 GRAT No. 2. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy 2019 GRAT No. 1 | 150,000 |
Reported balance
Holding disclosure · report date 2020-05-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 150,000 F2: Shares held by the 2019 GRAT No. 1. The Reporting Person is a trustee and beneficiary of the 2019 GRAT No. 1 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2019 GRAT No. 1. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Sons | 4,000 |
Reported balance
Holding disclosure · report date 2020-05-14 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by James M. Frates 2018 Grantor Retained Annuity Trust No. 2 dated May 25, 2018 (the "2018 GRAT No. 2"). The Reporting Person is a trustee and beneficiary of the 2018 GRAT No. 2 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2018 GRAT No. 2.
F2: Shares held by the 2019 GRAT No. 1. The Reporting Person is a trustee and beneficiary of the 2019 GRAT No. 1 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2019 GRAT No. 1.
F3: These options are fully vested in accordance with their terms.
Amylyx Pharmaceuticals, Inc.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 233,625 |
Ending reported balance
After 2026-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-10 · Sale · Disposed 9,768 · Balance 234,667 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.805 to $32.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 2 · 2026-09-10 · Sale · Disposed 1,042 · Balance 233,625 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $33.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 100,000 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 100,000 F4: Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 15,459 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 15,459 F5: Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 11,072 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,072 F6: Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 40,000 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 40,000 F7: Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.805 to $32.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $33.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F5: Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F6: Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F7: Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sage Therapeutics, Inc.
Report date July 31, 2025 · Filed July 31, 2025
Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 1
1 source rowRow 1 · 2025-07-31 · Other · Disposed 2,845 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2035-01-03 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-31 · Disposition to issuer · Disposed 19,154 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-31 · Disposition to issuer · Disposed 21,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.
F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2017 Filed Feb 27, 2017 22:46 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 2,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-008686 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Ordinary Shares · 2,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/26/2016. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/26/2016. Read SEC document |
| February 26, 2017 Filed Feb 27, 2017 22:46 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 852 | $52.98 | $45,138.96 |
DisclosureSEC source: 0001127602-17-008686 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,115 Read SEC document |
| February 26, 2017 Filed Feb 27, 2017 22:46 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-008686 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 22:59 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $54.57 | $0.00 |
DisclosureSEC source: 0001127602-17-007482 · form4.xml · derivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2027-02-17 F2 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/17/18. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 22:59 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 12,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007482 · form4.xml · derivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Ordinary Shares · 12,000 shares Expires not disclosed F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 23:54 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0001127602-16-070166 · form4.xml · derivative · entry 10 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,983 Underlying: Ordinary Shares · 10,000 shares Expires 2020-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 23:54 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $14.13 | $0.00 |
DisclosureSEC source: 0001127602-16-070166 · form4.xml · derivative · entry 9 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires 2017-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 23:54 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 100 | $55.20 | $5,520.00 |
DisclosureSEC source: 0001127602-16-070166 · form4.xml · nonDerivative · entry 4 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,342 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 23:54 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 24,900 | $54.72 | $1,362,612.66 |
DisclosureSEC source: 0001127602-16-070166 · form4.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,442 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.20 to $55.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 23:54 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 10,000 | $11.74 | $117,400.00 |
DisclosureSEC source: 0001127602-16-070166 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 23:54 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 15,000 | $14.13 | $211,950.00 |
DisclosureSEC source: 0001127602-16-070166 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 23:24 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0001127602-16-069524 · form4.xml · derivative · entry 11 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,983 Underlying: Ordinary Shares · 10,000 shares Expires 2020-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 23:24 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 13,731 | $0.00 Strike: $15.95 | $0.00 |
DisclosureSEC source: 0001127602-16-069524 · form4.xml · derivative · entry 10 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,731 shares Expires 2017-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 23:24 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 856 | $57.22 | $48,977.50 |
DisclosureSEC source: 0001127602-16-069524 · form4.xml · nonDerivative · entry 5 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,342 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.14 to $57.33. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 23:24 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 17,379 | $56.44 | $980,827.31 |
DisclosureSEC source: 0001127602-16-069524 · form4.xml · nonDerivative · entry 4 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,198 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.10 to $57.06. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 23:24 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 5,496 | $55.65 | $305,827.12 |
DisclosureSEC source: 0001127602-16-069524 · form4.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,577 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.09 to $56.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 23:24 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 10,000 | $11.74 | $117,400.00 |
DisclosureSEC source: 0001127602-16-069524 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 23:24 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 13,731 | $15.95 | $219,009.45 |
DisclosureSEC source: 0001127602-16-069524 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 18,579 shares received on December 5, 2016 pursuant to an annuity payment from the James M. Frates Grantor Retained Annuity Trust No. 2 dated November 25, 2015 (the "2015 GRAT No. 2") which was exempt from reporting obligations by virtue of Rule 16a-13 promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 23:02 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,042 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0001127602-16-067934 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,958 Underlying: Ordinary Shares · 6,042 shares Expires 2022-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 23:02 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,711 | $58.44 | $99,990.84 |
DisclosureSEC source: 0001127602-16-067934 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,763 Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 23:02 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,042 | $16.55 | $99,995.10 |
DisclosureSEC source: 0001127602-16-067934 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 01:04 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064471 · form4.xml · derivative · entry 8 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each performance restricted stock unit represented a contingent right to receive one ordinary share of Alkermes plc. F7 · derivative.exercise_date: This performance restricted stock unit, which was granted to the reporting person on March 3, 2014, is fully vested in accordance with its terms. F7 · derivative.expiration_date: This performance restricted stock unit, which was granted to the reporting person on March 3, 2014, is fully vested in accordance with its terms. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 01:04 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 2,353 | $46.43 | $109,249.79 |
DisclosureSEC source: 0001127602-16-064471 · form4.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,432 Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 01:04 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064471 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2016 Filed Oct 7, 2016 01:04 UTC | Alkermes plc. ALKS · Entity 2392 | GiftOrdinary Shares | 4,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064471 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,924 F1 · balance_after: Includes 9,760 shares received on June 2, 2016 pursuant to an annuity payment from the James M. Frates Grantor Retained Annuity Trust dated March 14, 2014 (the "2014 GRAT"), which was exempt from reporting obligations by virtue of Rule 16a-13 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 24,861 shares received on September 9, 2016 pursuant to an annuity payment from the James M. Frates Grantor Retained Annuity Trust dated May 29, 2015 (the "2015 GRAT"), which was exempt from reporting obligations by virtue of Rule 16a-13 promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.